98%
921
2 minutes
20
Structure-based drug design (SBDD) has become an alternative to high throughput screening (HTS) as it reduces experimental costs and time. It works like a funnel, filtering out compounds that do not show good affinity (or score) toward a particular target, with known 3D structure.Here, we describe a protocol for structure-based drug design using a multi-level in silico approach, combining Molecular Docking, Virtual Screening, Molecular Dynamics Simulations and Free energy calculations to find new lead molecules for experimental testing, predict binding affinities and characterize binding modes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-0716-3147-8_15 | DOI Listing |
Eur J Pharm Biopharm
September 2025
Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Women, Child and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Unlabelled: The Media-Fill Test is a crucial procedure in the pharmaceutical industry, especially for the production of sterile drugs that do not undergo terminal sterilization (meaning they are prepared directly under aseptic conditions).The primary goal of the Media-Fill Test is to evaluate the overall effectiveness of the aseptic process in preventing microbial contamination. It doesn't serve to test the sterility of an individual production batch, but rather to: Validate the aseptic process, Qualify personnel, Identify critical points and Verify the environment.
View Article and Find Full Text PDFBioorg Chem
August 2025
Wenzhou Medical University, Wenzhou 325035, PR China; Zhejiang Cancer Hospital, Hangzhou 310022, PR China. Electronic address:
Transcriptional enhanced associate domain (TEAD), overexpressed in hepatocellular carcinoma (HCC) and inversely correlated to prognosis, has emerged as a promising target for HCC therapy. To date, no small-molecule inhibitors targeting TEAD have been reported for HCC treatment. In this study, a bioinformatic analysis has been performed and has demonstrated that TEAD is a promising target for therapeutic intervention in HCC.
View Article and Find Full Text PDFJ Clin Neurosci
September 2025
Department of Neurosurgery, LeHigh Valley Network, Allentown, PA, USA.
Introduction: The management of cerebral aneurysms in low- and middle-income countries (LMICs) faces significant barriers, including limited access to specialized neurosurgical care and equipment and dissipating human resources. Ghana's inaugural experience with cerebral aneurysm clipping, facilitated by the Global Brainsurgery Initiative (GBI), represent an attempt to address these challenges through international collaboration.
Methods: This case series details the outcomes of six patients who underwent cerebral aneurysm clipping procedures at two neurosurgical centers.
Nurs Open
September 2025
Department of Pharmacy Practice and Administration, Rutgers University, Ernest Mario School of Pharmacy, New Brunswick, New Jersey, USA.
Aim: To identify individuals at risk of falls and the factors contributing to their risk, we screened community-dwelling older adults using the Centers for Disease Control and Prevention's Stopping Elderly Accidents, Deaths, and Injuries (STEADI) Assessments.
Design: A descriptive correlational study design.
Methods: Fall risk screenings with community-dwelling older adults aged 65 or older were conducted during a virtual interprofessional education event (IPE) for fall risk screening.
BMJ Open
September 2025
ADAPTLab, Clinical Educational and Health Psychology, Psychology and Language Sciences, University College London, London, UK.
Introduction: Carers of people with non-memory-led dementias such as posterior cortical atrophy (PCA), primary progressive aphasia (PPA) and behavioural variant frontotemporal dementia (bvFTD) face unique challenges. Yet, little evidence-based support and guidance are available for this population. To address this gap in services, we have developed a novel, web-based educational programme: the Better Living with Non-memory-led Dementia programme (BELIDE).
View Article and Find Full Text PDF